Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO 63110, USA.
Ann Pharmacother. 2010 Jul-Aug;44(7-8):1141-51. doi: 10.1345/aph.1P088. Epub 2010 Jun 29.
Most literature available for unfractionated heparin (UFH) supports the use of actual body weight for dosing all patients, yet a small proportion of the patients in these studies were morbidly obese. The most appropriate dosing strategy for therapeutic UFH in this patient population is not clearly defined.
To better define appropriate UFH dosing strategies in morbidly obese patients and to evaluate the safety of a weight-based heparin nomogram in this patient population.
Patients with class III (morbid) obesity receiving therapeutic doses of a UFH infusion for greater than 24 hours were evaluated. Two comparator groups of overweight/class I -II obesity and normal/underweight patients were created by matching patients to the class III obesity group. Doses and times to therapeutic activated partial thromboplastin time (aPTT), bleeding rates, and mortality were assessed.
The mean infusion rate required to obtain a first therapeutic aPTT was 11.5 units/kg/h in the class III obesity group (n = 94) versus 12.5 units/kg/h and 13.5 units/kg/h for the overweight/class I-II obesity (n = 92) and normal/underweight (n = 87) groups, respectively (p = 0.001). The mean times to a first therapeutic aPTT were 21.3, 22.1, and 29.9 hours, respectively (p = 0.421). There was a statistically significant difference in the infusion rate required to obtain 2 consecutive therapeutic aPTTs between groups (p = 0.016), with higher weight groups requiring smaller (per kilogram actual body weight) infusion rates, but there was no significant difference in the time to reach 2 consecutive therapeutic aPTTs (p = 0.776). There was no significant difference in bleeding (p = 0.517) or mortality (p = 0.475) among groups.
Morbidly obese patients require smaller UFH infusion rates per kilogram actual body weight compared to patients with lower body mass indices. UFH dosing recommendations should be modified to reflect body mass index classification.
大多数关于未分级肝素(UFH)的文献都支持对所有患者使用实际体重进行剂量调整,但这些研究中的一小部分患者患有病态肥胖。对于这类患者人群,治疗性 UFH 的最佳剂量调整策略尚未明确界定。
更好地定义病态肥胖患者中适当的 UFH 剂量调整策略,并评估体重为基础的肝素剂量图表在该患者人群中的安全性。
评估了接受大于 24 小时治疗剂量 UFH 输注的 III 类(病态)肥胖患者。通过与 III 类肥胖组相匹配,创建了超重/1-2 类肥胖和正常/消瘦患者的两个对照组。评估了剂量、达到治疗性激活部分凝血活酶时间(aPTT)的时间、出血率和死亡率。
在 III 类肥胖组(n = 94)中,达到首次治疗性 aPTT 的平均输注率为 11.5 单位/公斤/小时,而在超重/1-2 类肥胖组(n = 92)和正常/消瘦组(n = 87)中,相应的输注率分别为 12.5 单位/公斤/小时和 13.5 单位/公斤/小时(p = 0.001)。达到首次治疗性 aPTT 的平均时间分别为 21.3、22.1 和 29.9 小时(p = 0.421)。组间达到 2 次连续治疗性 aPTT 的输注率要求存在统计学差异(p = 0.016),体重较高的组需要更小的(每公斤实际体重)输注率,但达到 2 次连续治疗性 aPTT 的时间无显著差异(p = 0.776)。组间出血(p = 0.517)或死亡率(p = 0.475)无显著差异。
与身体质量指数较低的患者相比,病态肥胖患者每公斤实际体重需要更小的 UFH 输注率。UFH 剂量建议应根据体重指数分类进行调整。